Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative

• Published in: Pediatric nephrology (Berlin, West) Vol. 28; no. 1; pp. 5 - 11
• Main Authors: Kashtan, Clifford E., Ding, Jie, Gregory, Martin, Gross, Oliver, Heidet, Laurence, Knebelmann, Bertrand, Rheault, Michelle, Licht, Christoph
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer-Verlag 01-01-2013; Springer; Springer Nature B.V
• Subjects: Age; Alport's syndrome; Care and treatment; Child; Clinical medicine; Clinical trials; Collaboration; Collagen; Diagnosis; Enzymes; Female; Genotype & phenotype; Hematuria; Humans; Intervention; Kidney diseases; Male; Males; Medicine; Medicine & Public Health; Mutation; Nephritis, Hereditary - drug therapy; Nephritis, Hereditary - genetics; Nephritis, Hereditary - physiopathology; Nephrology; Pediatrics; Review; Urology; Canada; United States > US; China; Germany; Angiotensin-converting enzyme inhibitor; Angiotensin receptor blocker; Alport syndrome; Proteinuria; Aldosterone inhibitor
• ISSN: 0931-041X; 1432-198X
• DOI: 10.1007/s00467-012-2138-4

We present clinical practice recommendations for the treatment of children with Alport syndrome who are not enrolled in clinical trials. Our goal is to promote early initiation of a standard therapeutic approach that will facilitate assessment of the safety and efficacy of the protocol. The treatment protocol is based on the reduction of proteinuria, intraglomerular pressure, and renal fibrosis via interference with the renin–angiotensin–aldosterone system.